FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder

Elizabeth A. Guancial, Lillian Werner, Joaquim Bellmunt, Aristotle Bamias, Toni K. Choueiri, Robert Ross, Fabio A. Schutz, Rachel S. Park, Robert J. O'Brien, Michelle S. Hirsch, Justine A. Barletta, David M. Berman, Rosina Lis, Massimo Loda, Edward C. Stack, Levi A. Garraway, Markus Riester, Franziska Michor, Philip W. Kantoff, Jonathan E. Rosenberg

Research output: Contribution to journalArticle

Abstract

While fibroblast growth factor receptor 3 (FGFR3) is frequently mutated or overexpressed in nonmuscle-invasive urothelial carcinoma (UC), the prevalence of FGFR3 protein expression and mutation remains unknown in muscle-invasive disease. FGFR3 protein and mRNA expression, mutational status, and copy number variation were retrospectively analyzed in 231 patients with formalin-fixed paraffin-embedded primary UCs, 33 metastases, and 14 paired primary and metastatic tumors using the following methods: immunohistochemistry, NanoString nCounterTM, OncoMap or Affymetrix OncoScanTM array, and Gain and Loss of Analysis of DNA and Genomic Identification of Significant Targets in Cancer software. FGFR3 immunohistochemistry staining was present in 29% of primary UCs and 49% of metastases and did not impact overall survival (P = 0.89, primary tumors; P = 0.78, metastases). FGFR3 mutations were observed in 2% of primary tumors and 9% of metastases. Mutant tumors expressed higher levels of FGFR3 mRNA than wild-type tumors (P 

Original languageEnglish (US)
Pages (from-to)835-844
Number of pages10
JournalCancer Medicine
Volume3
Issue number4
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Receptor, Fibroblast Growth Factor, Type 3
Urinary Bladder
Carcinoma
Neoplasm Metastasis
Neoplasms
Immunohistochemistry
Messenger RNA
Mutation
Paraffin
Formaldehyde
Proteins
Software
Staining and Labeling
Muscles
Survival
DNA

Keywords

  • Biomarker
  • Bladder cancer
  • FGFR3
  • Metastatic urothelial carcinoma
  • Muscle-invasive urothelial carcinoma
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Guancial, E. A., Werner, L., Bellmunt, J., Bamias, A., Choueiri, T. K., Ross, R., ... Rosenberg, J. E. (2014). FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Medicine, 3(4), 835-844. https://doi.org/10.1002/cam4.262

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. / Guancial, Elizabeth A.; Werner, Lillian; Bellmunt, Joaquim; Bamias, Aristotle; Choueiri, Toni K.; Ross, Robert; Schutz, Fabio A.; Park, Rachel S.; O'Brien, Robert J.; Hirsch, Michelle S.; Barletta, Justine A.; Berman, David M.; Lis, Rosina; Loda, Massimo; Stack, Edward C.; Garraway, Levi A.; Riester, Markus; Michor, Franziska; Kantoff, Philip W.; Rosenberg, Jonathan E.

In: Cancer Medicine, Vol. 3, No. 4, 2014, p. 835-844.

Research output: Contribution to journalArticle

Guancial, EA, Werner, L, Bellmunt, J, Bamias, A, Choueiri, TK, Ross, R, Schutz, FA, Park, RS, O'Brien, RJ, Hirsch, MS, Barletta, JA, Berman, DM, Lis, R, Loda, M, Stack, EC, Garraway, LA, Riester, M, Michor, F, Kantoff, PW & Rosenberg, JE 2014, 'FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder', Cancer Medicine, vol. 3, no. 4, pp. 835-844. https://doi.org/10.1002/cam4.262
Guancial EA, Werner L, Bellmunt J, Bamias A, Choueiri TK, Ross R et al. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Medicine. 2014;3(4):835-844. https://doi.org/10.1002/cam4.262
Guancial, Elizabeth A. ; Werner, Lillian ; Bellmunt, Joaquim ; Bamias, Aristotle ; Choueiri, Toni K. ; Ross, Robert ; Schutz, Fabio A. ; Park, Rachel S. ; O'Brien, Robert J. ; Hirsch, Michelle S. ; Barletta, Justine A. ; Berman, David M. ; Lis, Rosina ; Loda, Massimo ; Stack, Edward C. ; Garraway, Levi A. ; Riester, Markus ; Michor, Franziska ; Kantoff, Philip W. ; Rosenberg, Jonathan E. / FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. In: Cancer Medicine. 2014 ; Vol. 3, No. 4. pp. 835-844.
@article{219efdd7c7d6498ea679963440280b2a,
title = "FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder",
abstract = "While fibroblast growth factor receptor 3 (FGFR3) is frequently mutated or overexpressed in nonmuscle-invasive urothelial carcinoma (UC), the prevalence of FGFR3 protein expression and mutation remains unknown in muscle-invasive disease. FGFR3 protein and mRNA expression, mutational status, and copy number variation were retrospectively analyzed in 231 patients with formalin-fixed paraffin-embedded primary UCs, 33 metastases, and 14 paired primary and metastatic tumors using the following methods: immunohistochemistry, NanoString nCounterTM, OncoMap or Affymetrix OncoScanTM array, and Gain and Loss of Analysis of DNA and Genomic Identification of Significant Targets in Cancer software. FGFR3 immunohistochemistry staining was present in 29{\%} of primary UCs and 49{\%} of metastases and did not impact overall survival (P = 0.89, primary tumors; P = 0.78, metastases). FGFR3 mutations were observed in 2{\%} of primary tumors and 9{\%} of metastases. Mutant tumors expressed higher levels of FGFR3 mRNA than wild-type tumors (P ",
keywords = "Biomarker, Bladder cancer, FGFR3, Metastatic urothelial carcinoma, Muscle-invasive urothelial carcinoma, Targeted therapy",
author = "Guancial, {Elizabeth A.} and Lillian Werner and Joaquim Bellmunt and Aristotle Bamias and Choueiri, {Toni K.} and Robert Ross and Schutz, {Fabio A.} and Park, {Rachel S.} and O'Brien, {Robert J.} and Hirsch, {Michelle S.} and Barletta, {Justine A.} and Berman, {David M.} and Rosina Lis and Massimo Loda and Stack, {Edward C.} and Garraway, {Levi A.} and Markus Riester and Franziska Michor and Kantoff, {Philip W.} and Rosenberg, {Jonathan E.}",
year = "2014",
doi = "10.1002/cam4.262",
language = "English (US)",
volume = "3",
pages = "835--844",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder

AU - Guancial, Elizabeth A.

AU - Werner, Lillian

AU - Bellmunt, Joaquim

AU - Bamias, Aristotle

AU - Choueiri, Toni K.

AU - Ross, Robert

AU - Schutz, Fabio A.

AU - Park, Rachel S.

AU - O'Brien, Robert J.

AU - Hirsch, Michelle S.

AU - Barletta, Justine A.

AU - Berman, David M.

AU - Lis, Rosina

AU - Loda, Massimo

AU - Stack, Edward C.

AU - Garraway, Levi A.

AU - Riester, Markus

AU - Michor, Franziska

AU - Kantoff, Philip W.

AU - Rosenberg, Jonathan E.

PY - 2014

Y1 - 2014

N2 - While fibroblast growth factor receptor 3 (FGFR3) is frequently mutated or overexpressed in nonmuscle-invasive urothelial carcinoma (UC), the prevalence of FGFR3 protein expression and mutation remains unknown in muscle-invasive disease. FGFR3 protein and mRNA expression, mutational status, and copy number variation were retrospectively analyzed in 231 patients with formalin-fixed paraffin-embedded primary UCs, 33 metastases, and 14 paired primary and metastatic tumors using the following methods: immunohistochemistry, NanoString nCounterTM, OncoMap or Affymetrix OncoScanTM array, and Gain and Loss of Analysis of DNA and Genomic Identification of Significant Targets in Cancer software. FGFR3 immunohistochemistry staining was present in 29% of primary UCs and 49% of metastases and did not impact overall survival (P = 0.89, primary tumors; P = 0.78, metastases). FGFR3 mutations were observed in 2% of primary tumors and 9% of metastases. Mutant tumors expressed higher levels of FGFR3 mRNA than wild-type tumors (P 

AB - While fibroblast growth factor receptor 3 (FGFR3) is frequently mutated or overexpressed in nonmuscle-invasive urothelial carcinoma (UC), the prevalence of FGFR3 protein expression and mutation remains unknown in muscle-invasive disease. FGFR3 protein and mRNA expression, mutational status, and copy number variation were retrospectively analyzed in 231 patients with formalin-fixed paraffin-embedded primary UCs, 33 metastases, and 14 paired primary and metastatic tumors using the following methods: immunohistochemistry, NanoString nCounterTM, OncoMap or Affymetrix OncoScanTM array, and Gain and Loss of Analysis of DNA and Genomic Identification of Significant Targets in Cancer software. FGFR3 immunohistochemistry staining was present in 29% of primary UCs and 49% of metastases and did not impact overall survival (P = 0.89, primary tumors; P = 0.78, metastases). FGFR3 mutations were observed in 2% of primary tumors and 9% of metastases. Mutant tumors expressed higher levels of FGFR3 mRNA than wild-type tumors (P 

KW - Biomarker

KW - Bladder cancer

KW - FGFR3

KW - Metastatic urothelial carcinoma

KW - Muscle-invasive urothelial carcinoma

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84924416523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924416523&partnerID=8YFLogxK

U2 - 10.1002/cam4.262

DO - 10.1002/cam4.262

M3 - Article

C2 - 24846059

AN - SCOPUS:84924416523

VL - 3

SP - 835

EP - 844

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 4

ER -